tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2022 Dec 9.
doi: 10.1080/14760584.2023.2156861. Online ahead of print.
Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review
Cristian Sandoval[SUP] 1 2 3 [/SUP], Daniela Guerrero[SUP] 1 [/SUP], Joham Muñoz[SUP] 1 [/SUP], Karina Godoy[SUP] 4 5 [/SUP], Vanessa Souza-Mello[SUP] 6 [/SUP], Jorge Farías[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Vaccines prevent disease and disability; save lives and represent a good assessment of health interventions. Several systematic reviews on the efficacy and effectiveness of COVID-19 vaccines have been published, but the immunogenicity and safety of these vaccines should also be addressed.
Areas covered: This systemic investigation sought to explain the efficacy, immunogenicity, and safety of new vaccination technologies against SARS-CoV-2 in people over 18 years old. Original research studying the effectiveness on mRNA, protein subunit vaccines, and viral vector vaccines against SARS-CoV-2 in people over 18 years old was analyzed. Several databases (Web of Science, Scopus, MEDLINE and EMBASE) were searched between 2012 and November 2022 for English-language papers using text and MeSH terms related to SARS-CoV-2, mechanism, protein subunit vaccine, viral vector, and mRNA. The protocol was registered on PROSPERO, CRD42022341952. Study quality was assessed using the NICE methodology. We looked at a total of six original articles. All studies gathered and presented quantitative data.
Expert opinion: Our results suggest that new vaccinations could have more than 90% efficacy against SARS-CoV-2, regardless of the technology used. Furthermore, adverse reactions go from mild to moderate, and good immunogenicity can be observed for all vaccine types.
Keywords: COVID vaccines; coronavirus; number of doses; vaccination; vaccine efficacy; vaccine platforms.
. 2022 Dec 9.
doi: 10.1080/14760584.2023.2156861. Online ahead of print.
Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review
Cristian Sandoval[SUP] 1 2 3 [/SUP], Daniela Guerrero[SUP] 1 [/SUP], Joham Muñoz[SUP] 1 [/SUP], Karina Godoy[SUP] 4 5 [/SUP], Vanessa Souza-Mello[SUP] 6 [/SUP], Jorge Farías[SUP] 2 [/SUP]
Affiliations
- PMID: 36484136
- DOI: 10.1080/14760584.2023.2156861
Abstract
Introduction: Vaccines prevent disease and disability; save lives and represent a good assessment of health interventions. Several systematic reviews on the efficacy and effectiveness of COVID-19 vaccines have been published, but the immunogenicity and safety of these vaccines should also be addressed.
Areas covered: This systemic investigation sought to explain the efficacy, immunogenicity, and safety of new vaccination technologies against SARS-CoV-2 in people over 18 years old. Original research studying the effectiveness on mRNA, protein subunit vaccines, and viral vector vaccines against SARS-CoV-2 in people over 18 years old was analyzed. Several databases (Web of Science, Scopus, MEDLINE and EMBASE) were searched between 2012 and November 2022 for English-language papers using text and MeSH terms related to SARS-CoV-2, mechanism, protein subunit vaccine, viral vector, and mRNA. The protocol was registered on PROSPERO, CRD42022341952. Study quality was assessed using the NICE methodology. We looked at a total of six original articles. All studies gathered and presented quantitative data.
Expert opinion: Our results suggest that new vaccinations could have more than 90% efficacy against SARS-CoV-2, regardless of the technology used. Furthermore, adverse reactions go from mild to moderate, and good immunogenicity can be observed for all vaccine types.
Keywords: COVID vaccines; coronavirus; number of doses; vaccination; vaccine efficacy; vaccine platforms.